Fig. 2From: Clot time ratio (CTR) and relation to treatment outcome in patients with atrial fibrillation treated with RivaroxabanClot time ratio in patients without and with bleeds. Individual CTRs (white) from sampling 1, 2 and 3 and the mean CTR (grey) for patients on Rivaroxaban 20 without bleeds (circles) and with bleeds (diamonds). The dashed lines represent the first and third quartiles (PQ1−Q3) for patients on 20 mg RivaroxabanBack to article page